MARKET

RVMD

RVMD

REVOLUTION MEDICINES, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

31.27
-0.89
-2.77%
Closed 16:00 02/28 EST
OPEN
31.64
PREV CLOSE
32.16
HIGH
32.51
LOW
30.46
VOLUME
399.35K
TURNOVER
--
52 WEEK HIGH
33.98
52 WEEK LOW
27.15
MARKET CAP
1.78B
P/E (TTM)
-29.0667
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of RVMD and other stocks commission-free!

Open a Webull account and fund it to get a free stock

RVMD News

More
  • The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy
  • Benzinga · 1d ago
  • Investors Scrambled to Buy This Biotech IPO
  • MotleyFool.com · 02/21 16:00
  • The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion
  • Benzinga · 02/21 12:46
  • The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA
  • Benzinga · 02/19 12:21

Industry

Biotechnology & Medical Research
-0.13%
Pharmaceuticals & Medical Research
+5.97%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About RVMD

Revolution Medicines, Inc. is a clinical-stage precision oncology company. The Company is focused on developing targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on the renin angiotensin system (RAS) and mammalian target of rapamycin (mTOR) signaling pathways. The Company’s pipeline includes RMC-4630, a clinical-stage drug candidate that is designed to selectively inhibit the activity of SHP2. Additionally, the Company is developing a portfolio of inhibitors of other key frontier oncology targets within the notorious RAS pathway, as well as the related mTOR signaling cascade. These include inhibitors of multiple mutant RAS proteins and son of sevenless homolog one (SOS1), as well as RMC-5552. RMC-5552 is a selective inhibitor of mammalian target of rapamycin complex one (mTORC1) that is designed to preserve the tumor suppressive activity.
More

Webull offers kinds of Revolution Medicines Inc stock information, including NASDAQ:RVMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RVMD stock news, and many more online research tools to help you make informed decisions.